Friday, 16 Nov 2018

You are here

Autoimmunity in the Setting of Primary Immunodeficiency

There are many avenues for interdisciplinary collaboration within rheumatology, as our specialty encompasses every organ system and diseases with protean manifestations. The intersection of rheumatology and immunology is well known and has become increasingly important, given the association of autoimmune conditions with many of the primary immunodeficiency syndromes. This intersection was highlighted today at ACR by two excellent abstracts.

The first was presented during the plenary session and was the result of a multi-center collaboration – Screening of patients with adult-onset idiopathic polyarteritis nodosa for deficiency of adenosine deaminiase 2 (DADA2) (abstract #2790). DADA2 is a rare genetic disorder associated with inflammation in various tissues, including vasculitis and risk of stroke.  In particular it is known to be associated with polyarteritis nodosa (PAN). The investigators of this study looked at the prevalence of DADA2 in patients with presumed idiopathic PAN. 117 patients with idiopathic PAN (all negative for hepatitis B) were screened for mutations in ADA2 and 6.8% had rare missence variants in ADA2. While there were no clinical differences between PAN patients with or without these mutations, this may have implications in screening family members as well as for treatment, as TNF inhibitors are often used to treat DAD2, but are not often used for PAN.

The second abstract (#2838), presented by Kevin Byram, was a study examining what are the most common primary immunodeficiency (PID) syndromes associated with vasculitis. They did this by querying the USIDNET, a national consortium of PID patients, for vasculitis cases. 76 patients with vasculitis (out of 4,888 PID cases) were identified. The most common PID associations were common variable immunodeficiency (38%) and Wiskott-Aldrich Syndrome (26%). Interestingly, CNS vasculitis was the most common specific vasculitis syndrome identified (14%), and vasculitis cases were reported to be present before or at the time of PID diagnosis ~50% of the time. While vasculitis is an uncommon complication of PID, it is important for rheumatologists to be aware of this entity.

 

 

 

Add new comment

More Like This

Pilot Data on Rituximab in Henoch-Schonlein Purpura

Management of Henoch-Schonlein purpura (HSP) can be challenging as supportive care and avoidance of corticosteroids are often insufficient options. A new series of case reports and literature review of steroid refractory HSP suggests that rituximab may be effective in reducing hospital admissions, overall steroid use, and is capable of inducing remission.

Scleroderma Expert Treatment Preferences

Frustration may be the word that best characterizes many scleroderma management plans - owing to a lack of trials, lack of agreement and lack of clear guidance on management.

A panel of concerned experts  on systemic sclerosis (SSc) set out to develop consensus on SSc treatment algorithms.

IgG4-Related Disease: First Draft Criteria Presented at ACR 2018

As Dr. John Stone, MD, MPH recounted in his presentation regarding the new ACR/EULAR Classification Criteria for IgG4-Related Disease (IgG4-RD), only 15 years prior, IgG4-related disease was an unknown entity in the medical community.

Update on Myositis

The ACR/ARHP 2018 national meeting in Chicago presented us with opportunities to learn more about inflammatory myositis. A particularly interesting lecture was HOT topics in myositis. There were a few abstracts on MDA-5 related disease and a few on new or repurposed medications for dermatomyositis which will be covered here.

Checkpoint Inhibitor-related Myositis – Something Different

As expected, this year’s ACR meeting saw an upswing in the number of abstracts on immune related adverse events from checkpoint inhibitor therapy compared to last year. With the increase in approved indications for checkpoint inhibitors (CPIs), rheumatologists everywhere are going to be getting referrals for rheumatic irAEs.